Loading stock data…
BDTX
$1.90+0.05 (+2.70%)
After Hours$1.91+0.01 (+0.53%)· Last close Jun 9
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Black Diamond Therapeutics, Inc. in the Healthcare sector is trading at $1.90. Wall Street consensus targets $9.86 (7 analysts), implying a +418.8% move over the next 12 months. The stock is currently near its 52-week low of $1.84, remaining 34.9% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +418.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.90
Potential Downside
0%
Whystock Fair Value$1.90
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.43%
Volume
Today's trading volume
1.71M
Recent News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.